- Home
- KROS vs MYD Comparison
KROS vs MYD Comparison
Compare KROS & MYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- MYD
- Stock Information
- Founded
- KROS 2015
- MYD 1991
- Country
- KROS United States
- MYD United States
- Employees
- KROS N/A
- MYD N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- MYD Investment Bankers/Brokers/Service
- Sector
- KROS Health Care
- MYD Finance
- Exchange
- KROS Nasdaq
- MYD Nasdaq
- Market Cap
- KROS 558.9M
- MYD 456.4M
- IPO Year
- KROS 2020
- MYD N/A
- Fundamental
- Price
- KROS $13.37
- MYD $10.05
- Analyst Decision
- KROS Buy
- MYD
- Analyst Count
- KROS 13
- MYD 0
- Target Price
- KROS $20.63
- MYD N/A
- AVG Volume (30 Days)
- KROS 637.6K
- MYD 253.1K
- Earning Date
- KROS 08-06-2025
- MYD 01-01-0001
- Dividend Yield
- KROS N/A
- MYD 4.55%
- EPS Growth
- KROS N/A
- MYD N/A
- EPS
- KROS 0.11
- MYD N/A
- Revenue
- KROS $214,713,000.00
- MYD N/A
- Revenue This Year
- KROS $5,006.76
- MYD N/A
- Revenue Next Year
- KROS N/A
- MYD N/A
- P/E Ratio
- KROS $123.16
- MYD N/A
- Revenue Growth
- KROS 91657.70
- MYD N/A
- 52 Week Low
- KROS $9.12
- MYD $8.76
- 52 Week High
- KROS $72.37
- MYD $11.30
- Technical
- Relative Strength Index (RSI)
- KROS 42.27
- MYD 52.49
- Support Level
- KROS $13.25
- MYD $9.96
- Resistance Level
- KROS $13.99
- MYD $10.08
- Average True Range (ATR)
- KROS 0.36
- MYD 0.07
- MACD
- KROS -0.06
- MYD 0.02
- Stochastic Oscillator
- KROS 20.75
- MYD 71.05
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.